Serna Bio

Serna Bio is an innovative biotechnology company that leverages artificial intelligence (AI) and advanced data analytics to revolutionize RNA-targeted drug discovery. By focusing on RNA-small molecule interactions, Serna Bio aims to develop groundbreaking therapies for notoriously challenging targets, including undruggable proteins and non-coding RNA. The company is committed to bridging the gap in understanding how RNA can be effectively targeted with small molecules, a field that remains relatively nascent compared to the well-established domain of protein-targeted drugs.

The potential of RNA-targeting therapies is immense, as approximately 85% of the human genome is transcribed into RNA, yet only a small percentage codes for proteins. This realization motivates Serna Bio to explore the untapped opportunities within the druggable transcriptome. Their proprietary Discovery Platform drives the development of first-in-class small molecule programs intended for both human and non-human biological applications. Serna Bio's diverse and dedicated team includes experts in machine learning, novel chemistry, and RNA biology, all working towards unveiling new mechanisms of action for therapeutic interventions. By tackling these formidable challenges, Serna Bio aspires to shine a light on the dark genome and make a lasting impact in genetic medicine.